A detailed history of New Edge Advisors, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 992 shares of VKTX stock, worth $51,117. This represents 0.0% of its overall portfolio holdings.

Number of Shares
992
Previous 11,524 91.39%
Holding current value
$51,117
Previous $610,000 89.84%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$49.84 - $70.47 $524,914 - $742,190
-10,532 Reduced 91.39%
992 $62,000
Q2 2024

Aug 15, 2024

SELL
$47.39 - $80.2 $99,187 - $167,858
-2,093 Reduced 15.37%
11,524 $610,000
Q1 2024

May 14, 2024

BUY
$17.4 - $94.5 $226,600 - $1.23 Million
13,023 Added 2192.42%
13,617 $1.12 Million
Q4 2023

Feb 13, 2024

BUY
$9.24 - $19.64 $5,488 - $11,666
594 New
594 $11,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.95B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.